why choose us

First received: April 03, 2023

Clinical Trial: A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Obesity or Overweight

Study Type: INTERVENTIONAL


Official Title: Efficacy and Safety of Cagrilintide S.C. 2.4 mg in Combination With Semaglutide S.C. 2.4 mg (CagriSema S.C. 2.4 mg/2.4 mg) Once-Weekly in East Asian Participants With Overweight or Obesity

Brief Summary: This study will look at how well the new medicine CagriSema helps people with excess body weight lose weight compared to another medicine, semaglutide.The participants will receive one injection once a week.The study medicine will be injected with a thin needle, typically in the stomach, thighs or upper arms.The study will last for about 1½ years.

Read more